Efficacy and safety of micafungin for invasive candida infections: A meta-analysis of randomized controlled trials

Chinese Medical Journal

Volumn 125, Issue 2, 2012, Pages 345-351

  Chen, Qian ^a   Lin, Mao Hu ^a   Chen, Meng Li ^a   Liu, Zhe Yuan ^a   Chai, Dong ^a   Wang, Rui ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Antifungal agent; Invasive candida infections; Meta analysis; Micafungin

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN;

ABDOMINAL PAIN; ANEMIA; ARTICLE; BACKACHE; CANDIDEMIA; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; INJECTION SITE REACTION; INVASIVE CANDIDIASIS; LEUKOPENIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RIGOR; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; ECHINOCANDINS; HUMANS; LIPOPEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84862935136     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.02.033     Document Type: Article

References (45)

1. Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164-1170.
2. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-630.
3. Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis 2005; 41: 1455-1460.
4. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
5. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-643.
6. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
7. Darouiche RO. Oropharyngeal and oesophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998; 26: 259-272.
8. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996; 124: 633-642.
9. Wilcox CM, Darouiche RO, Laine L, Moskovitz BL, Mallegol I, Wu J. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of oesophageal candidiasis. J Infect Dis 1997; 176: 227-232.
10. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother 1996; 40: 279-291.
11. Powderly WG, Mayer KH, Perfect JR. Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res Hum Retroviruses 1999; 15: 1405-1412.
12. Gudlaugsson O, Gillespie S, Lee K. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-1177.
13. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20: 1531-1534.
14. Fridkin SK. Candidemia is costly, plain and simple. Clin Infect Dis 2005; 41: 1240-1241.
15. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-1239.
16. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189.
17. Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007; 67: 269-298.
18. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006; 43: 215-222.
19. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000; 31: 1155-1163.
20. Ullmann J, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006; 43: e29-e38.
21. White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27: 296-302.
22. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003; 3: 772-785.
23. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-693.
24. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000; 30: 653-657.
25. Denning DW. Echinocandins: a new class of antifungal. J Antimicrob Chemother 2002; 49: 889-891.
26. Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44: 57-62.
27. Warn PA, Sharp A, Morrissey G, Denning DW. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J Antimicrob Chemother 2002; 50: 1071-1074.
28. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
29. de Wet NTE, Bester AJ, Viljoen JJ, Filho F, Suleiman JM, Ticona E, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21: 899-907.
30. Pappas PG, Rotstein CMF, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-893.
31. de Wet NTE, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF, Della Negra M, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842-849.
32. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-1527.
33. Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis 2008; 27: 820-826.
34. van Burik JAH, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-1416.
35. Hiramatsu Y, Maeda Y, Fujii N, Saito T, Nawa Y, Hara M, et al. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol 2008; 88: 588-595.
36. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
37. Juang P. Update on new antifungal therapy. AACN Adv Crit Care 2007; 18: 253-260.
38. Sable CA, Strohmaier KM, Chodakewitz JA. Advances in antifungal therapy. Annu Rev Med 2008; 59: 361-379.
39. Jarvis B, Figgitt DP, Scott LJ. Micafungin. Drugs 2004; 64: 969-982.
40. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006; 42: 1171-1178.
41. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-1151.
42. Shi JY, Xu YC, Shi Y, Lu HX, Liu Y, Zhao WS, et al. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin. Chin Med J 2010; 123: 2706-2709.
43. Bartizal K, Gill CJ, Abruzzo GK, Flattery AM, Kong L, Scott PM, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2326-2332.
44. Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, Ruiz Pérez de Pipaón M, Hernández-Caballero C, Aznar-Martín J, et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010; 54: 3149-3154.
45. Morrison VA. Echinocandin antifungals: review and update. Expert Rev Anti Infect Ther 2006; 4: 325-342.